title: Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literature.
abstract: Treatment of metastatic renal cell carcinoma has radically changed during the last decade with the approval of new drugs, antiangiogenic agents and mammalian targets of rapamycin (m-TOR) inhibitors. The outcome of metastatic clear-cell carcinoma has been significantly improved, while other entities such as metastatic papillary renal cell carcinoma are still associated with a poor prognosis. To date, there is no standard guideline for metastatic non clear cell carcinoma. We report the case of a 68-year-old patient with a pulmonary metastatic evolution of a papillary kidney cancer who has had more than 3 years disease progression-free survival and is under ongoing treatment with m-TOR inhibitors.
authors.affiliation: Department of Medical Oncology, Hôpital Saint-André, Bordeaux, University Hospital-CHU Bordeaux, 1 Rue Jean Burguet, 33000, Bordeaux, France, amaury_daste@hotmail.com.
authors.forename: Amaury
authors.initials: A
authors.lastname: Daste
authors.forename: Marine
authors.initials: M
authors.lastname: Gross-Goupil
authors.forename: Sophie
authors.initials: S
authors.lastname: Roca
authors.forename: Jean-Christophe
authors.initials: JC
authors.lastname: Bernhard
authors.forename: Alain
authors.initials: A
authors.lastname: Ravaud
mesh_terms: D000368:Aged; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D000068338:Everolimus; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D047428:Protein Kinase Inhibitors; D000068338:Everolimus; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus